Recipharm completes strategic acquisition in India
Recipharm AB (publ) (“Recipharm” or the “Company”) announces today that it has now concluded the acquisition of Kemwell’s pharmaceutical businesses located in Bengaluru, India.Highlights · Expands position in emerging markets significantly, taking sales in these markets to more than SEK 800 million [1], dominated by sales directly to the fast-growing pharma market in India. · Major extension of Recipharm’s capabilities in India: · Provides access to significantly increased development operation both in scale and breadth of capabilities. · Already working with customers